This video, filmed at
the INR® in Los Angeles in July 2009, documents the improvement
sustained through three months following initiation of perispinal
etanercept (PSE) in a patient who has been flying to the INR®
in Los Angeles from Las Vegas weekly to receive the INR's unique
patented treatment. Please see Perispinal etanercept for neuroinflammatory
disorders. Edward Tobinick MD. Drug Discovery Today
2009 Feb; 14(3-4):168-77.The videos above are interviews discussing
and documenting the clinical response to initiation of anti-TNF
treatment (perispinal etanercept) at the INR. For
the published results please see Tobinick E, Gross H, Weinberger
A, Cohen H., TNF-alpha Modulation for Treatment of Alzheimer's
Disease: A 6-Month Pilot Study MedGenMed 2006; 8(2) :25;
Tobinick E., Perispinal etanercept for treatment of Alzheimer's
disease, Current Alzheimer Research 2007 Dec; 4(5):550-2;
Tobinick E, Gross H., Rapid improvement in verbal fluency
and aphasia following perispinal etanercept in Alzheimer's disease,
BMC Neurology 2008; 8:27; and Tobinick E., Perispinal
etanercept for neuroinflammatory disorders, Drug Discovery
Today 2009 Feb; 14(3-4):168-77.Institute for Neurological Research, a private medical group, inc.
100 UCLA Medical Plaza, Suites 205-210 Los Angeles, California
90095
Video2